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Nuclear xenobiotic receptor CAR activates transcription of the CYP2B6 gene by directly binding to
the distal enhancer PB responsive enhancer module (PBREM). This CAR-mediated activation is syn-
ergized by transcription factors early growth response 1 (EGR1) and hepatocyte-enriched nuclear
factor 4a (HNF4a) that bind to the proximal element OA response element KI (OAREKI) [Inoue, K.,
& Negishi, M. (2008). Nuclear receptor CAR requires early growth response 1 to activate the human
cytochrome P450 2B6 gene. J. Biol. Chem. 283, 10425–10432]. Two additional EGR1 binding sites
have now been found just downstream from PBREM. Internal deletion of EGR1 sites within the con-
text of the 1.8 kb CYP2B6 promoter, which contains both PBREM and OAREKI, revealed that the dis-
tal and proximal EGR1 sites are essential for EGR1 to synergize CAR-mediated transcription.
Chromatin conformation capture 3C assays demonstrated that ERG1 may loop the distal PBREM
towards the proximal OAREKI so that together, CAR and HNF4a synergistically activate the CYP2B6
promoter.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Hepatocytes have genes that encode xenobiotic metabolizing
enzymes and transporters which are induced following exposure
to xenobiotics including therapeutic drugs. Induction of these
genes helps to defend the body against the toxicity and carcinoge-
nicity of these xenobiotics, and also affects drug efﬁcacy and can
cause drug–drug interactions. Human cytochrome P450 2B6
(CYP2B6), one such enzyme, is clinically important as it metabo-
lizes many of the commonly used therapeutics and activates
anti-cancer pro-drugs such as cyclophosphamid and ifosfamide
[2]. Numerous drugs, such as phenobarbital (PB), phenytoin and
rifampicin, induce transcription of the CYP2B6 gene, an activity in
which the nuclear xenobiotic receptors CAR and pregnane X recep-
tor (PXR) perform the essential roles [3]. For example, PB speciﬁ-
cally translocates CAR from the cytoplasm into the nucleus [4],lf of the Federation of European Bi
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).leading the direct binding of CAR to the distal sequence called PB
responsive enhance module (PBREM) to trans-activate the CYP2B6
promoter [5]. While the distal PBREM is the primary CAR binding
site required for drug activation of the CYP2B6 promoter, our recent
study has shown that CAR also requires the 53-bp composite reg-
ulatory element OA response element KI (OAREKI) located in the
proximal promoter region to activate the CYP2B6 gene [1,6]. The
molecular mechanism by which the CYP2B6 promoter connects
the function of the distal PBREM with that of OAREKI to regulate
its activity, however, still remains elusive.
The OAREKI consists of the DR1, E-box and CACCC motifs, but
dose not contain a CAR binding sequence. Hepatocyte-enriched nu-
clear factor 4a (HNF4a), acting as the constitutive factor, always
occupies the DR1 site, whereas early growth response 1 (EGR1) is
the cellular signal-mediated inducible factor that binds to the CAC-
CC site [1]. All of these three transcription factors are essential for
the CYP2B6 promoter to be activated: CAR as the drug activated
factor, EGR1 as the signal-induced factor and HNF4a as the consti-
tutive factor. Intriguingly, our previous experiments including ChIP
analysis have revealed that CAR indirectly interacts with the OAR-
EKI as binding to CACCC site increases. These observations lead us
to hypothesize that EGR1 may facilitate the interaction of CAR with
the HNF4a on OAREKI to activate the CYP2B6 promoter. Here we
have identiﬁed and characterized two additional EGR1 bindingochemical Societies.
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formation capture (3C) assays to investigate the molecular mecha-
nism by which EGR1 facilitates CAR interaction with OAREKI.
2. Materials and methods
2.1. Reagents
1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzen (TCPOBOP) and
dimethylsulfoxide (DMSO) were purchased from Sigma Chemical
Co. (St. Lois, MO); poly(dI-dC)(dI-dC) from GE Healthcare Bio-Sci-
ence Corp. (Piscataway, NJ). The plasmid –pGL3basic and
pcDNA3.1-V5-His-TOPO were obtained from Promega (Madison,
WI) and Invitrogen (Carlsbad, CA), respectively. Normal Rabbit
IgG and antibodies against EGR1 {(588)X} were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA); V5 antibody from
Invitrogen.
2.2. Plasmids
The -1.8-kb CYP2B6 promoter was previously cloned into a basic
ﬁreﬂy luciferase reporter plasmid pGL3-basic [6]. Deletions were
constructed in the context of the -1.8-kb CYP2B6 promoter using
the Quick Change site-directed mutagenesis kit (Stratagene, TX)
and proper primers: DCA1 (268/244), DCA2 (1476/1467),
DCA3 (1526/1510) and DCA123 (268/244, 1476/1467
and 1526/1510). The promoters used for 3C assays were ampli-
ﬁed to add a XhoI site at both the 50 and 30 ends and were cloned
into a pGL3-basic plasmid. Human EGR1 cDNA was ampliﬁed from
Caco2 RNA and was cloned into pcDNA3.1-V5-His-TOPO plasmids
(Invitrogen). Various deletion mutants of EGR1 were likewise
constructed using the Quick Change site-directed mutagenesis
kit: pcDNA3.1-EGR1D1–283, pcDNA3.1-EGR1D3–283, pcDNA3.1-
EGR1D270–306 pcDNA3.1-EGR1D324–377, pcDNA3.1-EGR1D367–393,
pcDNA3.1-EGR1D422–543. All other plasmids used were previously
described in our laboratory.
2.3. Cells and transfection
HepG2 and Ym17 cells were cultured in minimal essential med-
ium supplemented with 10% (v/v) fetal bovine serum, antibiotics
(100 units/ml penicillin and 100 lg/ml streptomycin) and 2 mM
glutamine. Ym17 cells are a mCAR-expressing stable cell line de-
rived from HepG2 cells (6). For Luc reporter assays, cells were cul-
tured on a 24-well plate at a density of 3.5  105 cells per well for
24 h prior to transfection with a given plasmid or a combination of
multiple plasmids using FuGENE6 (Roche Diagnostics, Indianapo-
lis, IN). After 24 h transfection, the cells were treated with DMSO
or TCPOBOP (250 nM), for an additional 48 h and were harvested
for Luciferase assays using the Dual-Luciferase reporter assay sys-
tem (Promega).
2.4. Chromosome conformation capture (3C)
3C assays were performed as described previously with some
modiﬁcations [7]. Brieﬂy, 100 lg of nuclear extract prepared from
Ym17 cells treated with DMSO (24 h) or TCPOBOP (24 h) plus PMA
(1 h) were shaken with 50 ng of a given promoter at room temper-
ature for 45 min and were incubated with formaldehyde to cross-
link protein-DNA complexes. After glycines being added to stop
cross linking, complexes were precipitate by ethanol at 20 C,
Precipitates were dissolved in 80 ll of TE, digested by XhoI at
37 C for 2 h and were incubated for 20 min at 70 C to inactivate
the enzyme activity of XhoI. Digests were diluted in ligation buffer
not to exceed DNA concentration of over 0.5 ng/ll, from which
20 ng of DNA were ligated by T4 DNA ligase (2000 units, Promega)for 4 h at 16 C or by Quick ligase (Roche) for 5 min at room tem-
perature. After ligation, protein-DNA complexes were de-cross
linked by adding SDS and NaCl up to 1% and 0.3 M, respectively,
and treated overnight at 65 C and then treated with proteinase
K for additional 1 h at 55 C, from which DNA was puriﬁed by
PCR puriﬁcation kit (QIAGEN). Puriﬁed DNA was subjected to
ampliﬁcation: the 1769/31 and 682/618 regions for the
looped and linear DNA structures, respectively. For analysis by reg-
ular PCR, DNA was ampliﬁed by LA Taq (Takara), resolved by 1.5%
agarose gel and visualized by ethylene bromide. For real-time PCR
analysis using the 7900HT Fast Real-Time PCR System (Applied
Biosystems) using two primer sets (forward: AGGATAAAAGGCC-
CAGTTGGA, reverse: CTAAGATTGGGTGCTCATTGCA; for circulating,
forward: GGCCAGGATGGTCTCGAA, reverse: CCAGCACGTTGG-
GAAGCT for internal control).
2.5. Gel shift
Gel shift assays were performed with nuclear extracts prepared
from cells harvested from 4 conﬂuent 145 cm2 dishes for each drug
treatment using the procedures described previously [1,8].
3. Results and discussion
3.1. Requirement of both DNA binding and activation domain
EGR1 molecule consists of multiple domains such as the activa-
tion, repression and DNA binding domains (Fig. 1A). Domain-based
deletion mutants were constructed to delineate the region of EGR1
responsible for the synergistic activation of the CYP2B6 promoter.
Deletion of either the activation (m1) [9], repression (m2) [10] or
C-terminal (m6) [11] domain did not affect EGR1 binding to the
CACCC motif of OAREKI in gel shift assays (Fig. 1B). As expected,
two different deletions (m3 and m5) of the DNA binding domain
[11] resulted in the loss of binding ability. These mutants were
co-transfected into Ym17 cells to examine their capability to syn-
ergize the CAR–HNF4a mediated activation of the CYP2B6 pro-
moter. The m1, m3 and m5 mutants lost this capability, while
the m2 and m6 mutants fully retained it as observed with wild
type EGR1 (Fig. 1C). Thus, these results indicated that EGR1 re-
quires its activation and DNA binding domains to synergize the
CAR–HNF4a mediated transcription.
3.2. Requirement of both distal and proximal CACCC motifs
The CYP2B6 promoter is regulated by the two essential compos-
ite DNA sequences: the distal PBREM and the proximal OAREKI
(Fig. 2). Our previous study showed that EGR1 depends on its direct
interaction with the proximal CACCC motif (268/244) to syner-
gistically activate the 1.8 kb CYP2B6 promoter [1]. This proximal
CACCC motif (now designated CA1) is located at the 50-end of the
53 bp OAREKI (268/217) of the CYP2B6 promoter. Sequence-
based motif search of the 1.8 kb CYP2B6 promoter found two
additional CACCC motifs (CA2 and CA3) at just down stream of
the proximal PBREM (1733/1683): 1526CACACATTCACACC-
CAC1510 and 1476TGTGTGGGTG1467, respectively. Given this
ﬁnding, the role of these distal CA2 and CA3 motifs in the EGR1
mediated synergistic activation was investigated. Gel shift and
super-shift assays were performed using the CA1, CA2 and CA3 se-
quences as probes, conﬁrming that both CA2 and CA3 bound to
EGR1 in a similar manner to the CA1 (Fig. 3A). EGR1 appeared to
bind to all three probes: CA1, CA2 and CA3. Within the context
of the 1.8 kb CYP2B6 promoter, the CA1, CA2 and CA3 were inter-
nally deleted singularly or in combinations. Subsequently, these
deletion promoters were co-transfected with an EGR1 expression
plasmid into Ym17 cells so that their ability to be activated by
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Fig. 1. Structural domain-based function of early growth response 1 (EGR1). (A) Deletion map of EGR1 molecule. Domains of activation, repression and DNA binding (DBD)
are shown in boxes. Numeric numbers indicate residues beginning with and ending with for each deletion. (B) Gel shift assays to show binding of EGR1 and its deletion
mutants to CA rich region within CYP2B6 OA response element KI (OAREKI). Double-stranded 32P-end-labeled CA rich probe (253/242) was incubated with in vitro
translated EGR1 (WT), its mutants (m1–m6). m1-1, 1-2, 2, 3, 5, and 6: EGR1 deletion mutants lacking the activation domain (1–283) (3–283) [9], repression domain (270–
306) [10], DNA binding domain (324–377) [11], DNA binding domain (367–393) [11] and C-terminal region, respectively (422–543) [11]. Numbers indicate amino acid
residues. Autoradiography below is to show an equality of ERG1 proteins used for gel shift assays. EGR1 and its mutants were produced in vitro translated proteins in TNT
coupled reticulocyte lysate system (Promega) and [35S] Methionine (Amersham Biosciences, Piscataway, NJ), were separated on a 11% SDS–PAGE gel and were subjected to
autoradiography. Numeric numbers indicate sizes of molecular markers. (C) Transient transfection assays to show EGR1 activity. Ym17 cells were co-transfected by the
1.8 kb promoter of CYP2B6 with phRL-SV40 cells and were subsequently treated with either DMSO, or 250 nM 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzen (TCPOBOP).
Reporter activity was calculated by dividing ﬁreﬂy luciferase activity with Renilla luciferase activity.
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ACCCACAAACCCACACACCCACACA
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-1733 -1683
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Fig. 2. Motif map of CYP2B6 promoter. The 1.8 kb CYP2B6 promoter contains three CA rich regions: promoter of CYP2B6: CA1 (268/244), CA2 (1476/1467) and CA3
(1519/1511), which are positioned relative to PB responsive enhancer module (PBREM) (1733/1683) and OAREKI (268/217). The OAREKI sequence can be further
divided into CA1, E-box (233/228) and DR1 (229/217) regions.
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EGR1 approximately ﬁvefold. Although the single deletion of either
CA2 or CA3 resulted in the fully retention of the EGR1 activation,
the simultaneous deletion of both CA2 and CA3 decreased the pro-
moter activity to the same level as observed with the CA1 deletion
(Fig. 3B). The triple deletion of CA1, CA2 and CA3 completely abro-
gated the ability of EGR1 to activate the 1.8 kb CYP2B6 promoter.
These results suggested that both the proximal and distal CACCC
motifs are required for EGR1 to activate the 1.8 kb CYP2B6 pro-
moter. With respect to the two distal motifs, only one of the distal
CA2 and CA3 motifs was necessary for EGR1 activation in the pres-
ence of the proximal CA1 motif.
3.3. Looping distal PBREM close to proximal OAREKI
Requiring both the distal and proximal CA sites for EGR1 to syn-
ergize CAR-mediated transcription of CYP2B6 promoter led us to
hypothesize the presence of a looping mechanism that enables
physical access of CAR on the distal PBREM to HNF4a on the prox-imal OAREKI. Chromosome conformation capture (3C) assays
[12,13] were employed to explore this looping mechanism. A re-
cently developed in vitro version of 3C technique is an assay for
demonstrating DNA looping, in which two distant cis-acting ele-
ments in a head-to-head orientation are designed to be PCR ampli-
ﬁed as a single strand DNA in a head-to-tail orientation after
ligation when protein bindings enable them to come close one to
another [7]. 3C technique has already been employed to success-
fully show that the glucocorticoid receptor activates two promot-
ers that are looped close to the single glucocoroticoid response
element [12]. In our 3C assay with the 1.8 kb CYP2B6 promoter,
if looping occurs, PCR reaction should produce the 80 bp fragment
that contains a region of the sequence connecting PBREM and OAR-
EKI in head-to-tail orientation (Fig. 4A). When the 1.8 kb CYP2B6
promoter was incubated with nuclear proteins prepared from
Ym17 cells co-treated with TCPOBOP and phorbol 12-myristate
13-acetate (PMA), a dramatic ampliﬁcation of the 80 bp fragments
was observed and compared with the corresponding assay with
nuclear proteins from DMSO-treated Ym17 cells (Fig. 4B). No such
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K. Inoue, M. Negishi / FEBS Letters 583 (2009) 2126–2130 2129increase of the ampliﬁcation was detected when all three CA sites
were deleted from the 1.8 kb CYP2B6 promoter. In addition to the
regular PCR reaction, real-time PCR was also utilized in our 3C as-
says, showing approximately eightfold increase of ampliﬁcation
with the 1.8 kb CYP2B6 promoter by the nuclear extracts fromthe co-treated Ym17 cells and no increase with the promoter lack-
ing all three CA site (Fig. 4C). These results are consistent with the
hypothesis that EGR1, by binding to the CA sites, induces the loop-
ing of the distal PBREM closer to the proximal OAREKI within the
CYP2B6 promoter.
2130 K. Inoue, M. Negishi / FEBS Letters 583 (2009) 2126–2130In conclusion, we have now uncovered a novel looping mecha-
nism, whereby the distal PBREM close to the proximal OAREKI,
EGR1 enables CAR to cross-talk with HNF4a to synergistically acti-
vate CYP2B6 promoter. Multiple steps of protein-DNA and -protein
interactions expected to occur during this DNA looping still remain
a future subject of intense investigations. Functional cross talk of
CAR with HNF4a is well known its role in the transcriptional reg-
ulation of SULT2A1and various CYP genes [14–16], for one of which
indirect interactions of CAR with HNF4a are suggested [15].
Although the molecular mechanism by which EGR1 bends DNA
to loop the CYP2B6 promoter is not yet understood, it is reasonable
to think that ERG1 proteins at the distal and proximal CA sites may
directly or indirectly interact to loop PBREM close to OAREKI within
the CYP2B6 promoter. A presumed interaction of ERG1 with CAR
and/or HNF4a and/or the CAR interaction with HNF4a may simul-
taneously undergo in order for EGR1 to bend DNA. The concept of
DNA looping is widely accepted as a principle mechanism by which
two distantly separated cis-acting elements interact to regulate
transcription, another example of which is a possible EGR1
involvement in looping the RUSH-1a gene promoter for activation
[17]. CYP2B6 is one of the human P450 enzymes that metabolize
numerous therapeutic drugs. CAR mediates induction of CYP genes
by therapeutics, affecting drug efﬁcacy and causing drug–drug
interactions. Since CAR is not able to activate the CYP2B6 gene
without HNF4a and EGR1, understanding the molecular mecha-
nism of their cross talk should provide us with various ways to
control CYP2B6 activities with clinical implications.
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